Comparison of the immunogenicity and protective efficacy of ACAM2000, MVA, and vectored subunit vaccines for Mpox in rhesus macaques-Reference-Cited by-同舟云学术

Comparison of the immunogenicity and protective efficacy of ACAM2000, MVA, and vectored subunit vaccines for Mpox in rhesus macaques

Published:2024-03-27 Issue:740 Volume:16 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Jacob-Dolan Catherine¹²³^ORCID,Ty Darren¹^ORCID,Hope David¹^ORCID,McMahan Katherine¹^ORCID,Liu Jinyan¹^ORCID,Powers Olivia C.¹^ORCID,Cotter Catherine A.⁴^ORCID,Sciacca Michela¹^ORCID,Wu Cindy¹^ORCID,Borducchi Erica¹,Bouffard Emily¹,Richter Hannah¹^ORCID,Velasco Jason⁵,Teow Elyse⁵,Boursiquot Mona⁵^ORCID,Cook Anthony⁵,Feliciano Karen⁵^ORCID,Yalley-Ogunro Jake⁵,Seaman Michael S.¹^ORCID,Pessiant Laurent⁵^ORCID,Lewis Mark G.⁵^ORCID,Andersen Hanne⁵^ORCID,Moss Bernard⁴^ORCID,Barouch Dan H.¹²³^ORCID

Affiliation:

1. Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA.

2. Department of Immunology, Harvard Medical School, Boston, MA 02115, USA.

3. Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA 02139, USA.

4. Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MA 20852, USA.

5. Bioqual, Rockville, MD 20850, USA.

Abstract

The 2022–2023 mpox outbreak triggered vaccination efforts using smallpox vaccines that were approved for mpox, including modified vaccinia Ankara (MVA; JYNNEOS), which is a safer alternative to live replicating vaccinia virus (ACAM2000). Here, we compare the immunogenicity and protective efficacy of JYNNEOS by the subcutaneous or intradermal routes, ACAM2000 by the percutaneous route, and subunit Ad35 vector–based L1R/B5R or L1R/B5R/A27L/A33R vaccines by the intramuscular route in rhesus macaques. All vaccines provided robust protection against high-dose intravenous mpox virus challenge with the current outbreak strain, with ACAM2000 providing near complete protection and JYNNEOS and Ad35 vaccines providing robust but incomplete protection. Protection correlated with neutralizing antibody responses as well as L1R/M1R- and B5R/B6R-specific binding antibody responses, although additional immune responses likely also contributed to protection. This study demonstrates the protective efficacy of multiple vaccine platforms against mpox virus challenge, including both current clinical vaccines and vectored subunit vaccines.

Publisher

American Association for the Advancement of Science (AAAS)

Link

https://www.science.org/doi/pdf/10.1126/scitranslmed.adl4317

Reference44 articles.

1. CDC https://cdc.gov/poxvirus/mpox/response/2022/world-map.html (2023).

2. CDC https://cdc.gov/poxvirus/mpox/response/2022/index.html (2023).

3. Monkeypox

4. M. Malarkry M. Gruber Biological License Application approval letter for MVA-BN vaccine Bavarian Nordic (Food and Drug Administration 2019).

5. World Health Organization "Background document for the SAGE October 2022 session on monkeypox vaccines ” 16 November 2022; www.who.int/publications/i/item/WHO-MPX-Immunization-Background-2022.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rapid Decline of Mpox Antibody Responses Following MVA-BN Vaccination;2024-09-11

2. JYNNEOS vaccination induced short-lived neutralizing antibody responses to monkeypox virus in naïve individuals;2024-08-28